Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Authors
Keywords
Multiple myeloma, Tumor microenvironment, Immune responses, Immune escape, Immunotherapy
Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 73, Issue 8, Pages 1569-1589
Publisher
Springer Nature
Online
2016-01-22
DOI
10.1007/s00018-016-2135-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma
- (2015) A. McBride et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Immune checkpoint blockade in hematologic malignancies
- (2015) P. Armand BLOOD
- Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing
- (2015) P. Leone et al. BLOOD
- A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
- (2015) D. M. Benson et al. CLINICAL CANCER RESEARCH
- Immunosurveillance and therapy of multiple myeloma are CD226 dependent
- (2015) Camille Guillerey et al. JOURNAL OF CLINICAL INVESTIGATION
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow
- (2015) T Matthes et al. LEUKEMIA
- The burgeoning family of unconventional T cells
- (2015) Dale I Godfrey et al. NATURE IMMUNOLOGY
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
- (2015) Alexander M. Lesokhin et al. Science Translational Medicine
- Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma
- (2015) Kimberly A. Noonan et al. Science Translational Medicine
- The Regulatory Role of Invariant NKT Cells in Tumor Immunity
- (2015) Rosanna M. McEwen-Smith et al. Cancer Immunology Research
- Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival
- (2015) Giulia Di Lullo et al. OncoImmunology
- Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
- (2015) Weiqing Jing et al. Journal for ImmunoTherapy of Cancer
- TPL2 kinase regulates the inflammatory milieu of the myeloma niche
- (2014) C. Hope et al. BLOOD
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation
- (2014) Brenda De Keersmaecker et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Differentiation of Type 1 ILCs from a Common Progenitor to All Helper-like Innate Lymphoid Cell Lineages
- (2014) Christoph S.N. Klose et al. CELL
- CARTs on the Road for Myeloma
- (2014) M. V. Maus et al. CLINICAL CANCER RESEARCH
- Daratumumab granted breakthrough drug status
- (2014) Jacob P Laubach et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Allogeneic Stem Cell Transplantation for Multiple Myeloma
- (2014) William Bensinger HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Targeting the bone marrow microenvironment in multiple myeloma
- (2014) Yawara Kawano et al. IMMUNOLOGICAL REVIEWS
- The Alteration and Clinical Significance of Th1/Th2/Th17/Treg Cells in Patients with Multiple Myeloma
- (2014) Ping Feng et al. INFLAMMATION
- T cell-based targeted immunotherapies for patients with multiple myeloma
- (2014) Lei Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
- (2014) P. Sinha et al. JOURNAL OF IMMUNOLOGY
- Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma
- (2014) James Favaloro et al. LEUKEMIA & LYMPHOMA
- Eosinophils and Megakaryocytes Support the Early Growth of Murine MOPC315 Myeloma Cells in Their Bone Marrow Niches
- (2014) David Wong et al. PLoS One
- The cellular and molecular origin of tumor-associated macrophages
- (2014) R. A. Franklin et al. SCIENCE
- Mechanisms Driving Macrophage Diversity and Specialization in Distinct Tumor Microenvironments and Parallelisms with Other Tissues
- (2014) Eva Van Overmeire et al. Frontiers in Immunology
- Ontogeny of Myeloid Cells
- (2014) Ismé De Kleer et al. Frontiers in Immunology
- Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
- (2014) Kim De Veirman et al. Frontiers in Oncology
- Expansion of a Clonal CD8+CD57+ Large Granular Lymphocyte Population After Autologous Stem Cell Transplant in Multiple Myeloma
- (2013) Kristy L. Wolniak et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Tumor-associated macrophages as a prognostic parameter in multiple myeloma
- (2013) Elif Suyanı et al. ANNALS OF HEMATOLOGY
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
- (2013) G. T. Gorgun et al. BLOOD
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population
- (2013) D. Laoui et al. CANCER RESEARCH
- Clinical significance of macrophage heterogeneity in human malignant tumors
- (2013) Yoshihiro Komohara et al. CANCER SCIENCE
- Immunologic microenvironment and personalized treatment in multiple myeloma
- (2013) Marco Rossi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow
- (2013) I. R. Ramachandran et al. JOURNAL OF IMMUNOLOGY
- Increased Numbers of T Helper 17 Cells and the Correlation with Clinicopathological Characteristics in Multiple Myeloma
- (2013) C-J Shen et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells
- (2013) Isabel Jungkunz-Stier et al. LEUKEMIA & LYMPHOMA
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
- (2013) Hua Jiang et al. Molecular Oncology
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of Malignant Plasma Cell Proliferation by Eosinophils
- (2013) Tina W. Wong et al. PLoS One
- Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance
- (2013) C Bryant et al. Blood Cancer Journal
- Monitoring NK cell activity in patients with hematological malignancies
- (2013) Sébastien Viel et al. OncoImmunology
- Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment
- (2013) Simona Berardi et al. Journal of Oncology
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
- (2012) K Giannopoulos et al. BRITISH JOURNAL OF CANCER
- Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
- (2012) Jaehyup Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide enhances anti-myeloma cellular immunity
- (2012) Katarina Luptakova et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
- (2012) Walter M. T. Braga et al. Clinical & Developmental Immunology
- Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment--Poor Prognosis or New Therapeutic Opportunity
- (2012) L. A. Ridnour et al. CLINICAL CANCER RESEARCH
- Retinoic-Acid-Receptor-Related Orphan Nuclear Receptor Alpha Is Required for Natural Helper Cell Development and Allergic Inflammation
- (2012) Timotheus Y.F. Halim et al. IMMUNITY
- The establishment of the plasma cell survival niche in the bone marrow
- (2012) Van T. Chu et al. IMMUNOLOGICAL REVIEWS
- Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow
- (2012) E Van Valckenborgh et al. LEUKEMIA
- PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma
- (2012) Y Zheng et al. LEUKEMIA
- The role of natural killer cells in immunity against multiple myeloma
- (2012) James Godfrey et al. LEUKEMIA & LYMPHOMA
- What are regulatory T cells (Treg) regulating in cancer and why?
- (2012) Theresa L. Whiteside SEMINARS IN CANCER BIOLOGY
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling
- (2011) D. A. Hume et al. BLOOD
- Identification of the earliest natural killer cell-committed progenitor in murine bone marrow
- (2011) J. W. Fathman et al. BLOOD
- Monoclonal antibodies in the treatment of multiple myeloma
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
- (2011) Eric Tartour et al. CANCER AND METASTASIS REVIEWS
- Bone marrow and the control of immunity
- (2011) Ende Zhao et al. Cellular & Molecular Immunology
- Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
- (2011) Joan Bladé et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloma-Induced Alloreactive T Cells Arising in Myeloma-Infiltrated Bones Include Double-Positive CD8 + CD4 + T Cells: Evidence from Myeloma-Bearing Mouse Model
- (2011) Lisa M. Freeman et al. JOURNAL OF IMMUNOLOGY
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant
- (2011) Francesco Spina et al. LEUKEMIA & LYMPHOMA
- Microenvironment: Neighbourhood watch
- (2011) Virginia Hughes NATURE
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
- (2011) Bin-Zhi Qian et al. NATURE
- Eosinophils are required for the maintenance of plasma cells in the bone marrow
- (2011) Van Trung Chu et al. NATURE IMMUNOLOGY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammation and immune surveillance in cancer
- (2011) Melvyn T. Chow et al. SEMINARS IN CANCER BIOLOGY
- Staying alive: regulation of plasma cell survival
- (2011) Stuart G. Tangye TRENDS IN IMMUNOLOGY
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma
- (2010) K. Noonan et al. BLOOD
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
- (2010) R. H. Prabhala et al. BLOOD
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
- (2010) K. Movahedi et al. CANCER RESEARCH
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
- (2010) Cesar A. Corzo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma
- (2010) Alpana Sharma et al. LEUKEMIA & LYMPHOMA
- The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells
- (2010) Xiaoli Feng et al. MOLECULAR IMMUNOLOGY
- Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
- (2010) M. K. Brimnes et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Adhesion molecules—The lifelines of multiple myeloma cells
- (2010) Ben-Zion Katz SEMINARS IN CANCER BIOLOGY
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
- (2010) Thomas Condamine et al. TRENDS IN IMMUNOLOGY
- Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
- (2009) A. Lundqvist et al. BLOOD
- Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
- (2009) Y. Zheng et al. BLOOD
- Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
- (2009) M Lioznov et al. BONE MARROW TRANSPLANTATION
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
- (2009) Dharminder Chauhan et al. CANCER CELL
- Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked
- (2009) Marie von Lilienfeld-Toal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer
- (2009) P.-Y. Pan et al. CANCER RESEARCH
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
- (2009) F. Colotta et al. CARCINOGENESIS
- Heterogeneity and plasticity of T helper cells
- (2009) Jinfang Zhu et al. CELL RESEARCH
- Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells
- (2009) Mónica Bernal et al. HUMAN IMMUNOLOGY
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer
- (2008) D. H. Chang et al. BLOOD
- ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
- (2008) A. Soriani et al. BLOOD
- Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
- (2008) Jumei Shi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
- (2008) Li Yang et al. CANCER CELL
- Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
- (2008) Dan Zhu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
- (2008) P. Serafini et al. CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy
- (2008) W. Song et al. CLINICAL CANCER RESEARCH
- Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
- (2008) O. Murillo et al. CLINICAL CANCER RESEARCH
- Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells
- (2008) M C Minnema et al. LEUKEMIA
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
- (2008) M. Jinushi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started